West German Prostate Center | Priv.-Doz. Dr. Isabella Syring-Schmandke

Priv.-Doz. Dr. Isabella Syring-Schmandke

Specialist in urology
Drug-based tumor therapy
Fellow of the European Board of Urology (FEBU)

‍

Priv.-Doz. Dr. med. Isabella Syring-Schmandke is a highly qualified and experienced specialist in urology. She specializes in endourological procedures such as the minimally invasive treatment of benign prostate enlargement and bladder tumours as well as the surgical removal of ureteral and kidney stones. In addition, Priv.-Doz. Dr. Syring-Schmandke is distinguished by her outstanding expertise in the diagnosis and treatment of urological tumors, in particular prostate cancer. As part of her doctorate and habilitation, she has also written numerous scientific publications and congress presentations, which underline her comprehensive expertise and have been honored with awards.

‍

Professional career

- Specialist in urology, West German Prostate Center, KLINIK am RING, Cologne

- Specialist in Urology, Department of Urology, KLINIK am RING, Cologne

- Senior Physician for Urology, Clinic and Polyclinic for Urology and Pediatric Urology at Bonn University Hospital

- Specialist in urology, Clinic and Polyclinic for Urology and Pediatric Urology at Bonn University Hospital

- Scholarship holder of the "Ferdinand-Eisenberger Research Scholarship" of the German Society of Urology; Department of Prostate Cancer Research, Institute of Pathology, University Hospital Bonn

- Assistant physician, Clinic and Polyclinic for Urology and Pediatric Urology at Bonn University Hospital

- Studied medicine at the Rheinische Friedrich-Wilhelms-Universität Bonn

‍

Degrees

- Habilitation (Priv.-Doz.) on the topic "The role of the mediator complex in urological carcinomas"

- Additional title "Drug tumor therapy"

- Fellow of the European Board of Urology (F.E.B.U.)

- Specialist in urology - North Rhine Medical Association, Düsseldorf

- Doctorate (Dr.med.) on the topic "Experimental investigation of the tendency of uncoated and amorphous carbon-coated ureteral stents to incrust under the influence of albumin in artificial urine", Clinic and Polyclinic for Urology and Pediatric Urology at the University Hospital Bonn

- Medical state examination, Rheinische Friedrich-Wilhelms-Universität Bonn

‍

PD Dr. med. Isabella Syring-Schmandke is a member of the following organizations:

German Society for Urology (DGU)
European Association of Urology (EAU)
North Rhine-Westphalian Society for Urology e.V. (NRWGU)
German Society of Residents in Urology (GeSRU)
GeSRU Academics research network as a research group member

Original work

[1] Pia Paffenholz, Georg Landwehr, Christoph Alexander Seidel, Annika Poch, Carsten Bokemeyer, Richard Cathomas, Pailin Pongratanakul, Andreas Hiester, Peter Albers, Martin Pichler, Susanne Krege, Isabella Syring, Julia Heinzelbecker, Tim Nestler, David Pfister, Axel Heidenreich: Relapse-free and overall survival in patients with non-seminomatous testicular germ cell tumors with teratoma-free primaries. Journal of Clinical Oncology, 2023 February, 41 (6_suppl), 421-421

[2] Maximilian Peter Brandt, Christian Ruf, Klaus Peter Dieckmann, Isabella Syring, Christian Ruckes, Tim Nestler, HU Schmelz, Robert Dotzauer,Andreas Hiester, Pete Albers, Daniel Nettersheim, Christian Bolenz, Sven H Loosen, Axel Heidenreich, Darren Pfister, Axel Haferkamp,
Friedemann Zengerling, Pia Paffenholz, GESRU Academics Testis, Penile Cancer Group: Clinical characteristics, treatment patterns and relapse inpatients with clinical stage IS testicular cancer. World journal of urology, 2022 February; 1-8

[3] Jin Piao, John T Lafin, Cinzia G Scarpini, Michelle M Nuño, Isabella Syring, Klaus-Peter Dieckmann, Gazanfer Belge, Jörg Ellinger, JamesF:Amatruda, Aditya Bagrodia, Nicholas Coleman, Mark D Krailo, A Lindsay Frazier, Matthew J Murray: A multi-institutional pooled analysisdemonstrates that circulating miR-371a-3p alone is sufficient for testicular malignant germ cell tumor diagnosis. Clinical genitourinary cancer, 2021 December; 19 (6), 469-479

[4] MPJK Brandt, Christian Guido Ruf, Klaus Peter Dieckmann, Isabella Syring, Christian Ruckes, Andreas Hiester, Peter Albers, Bolenz Christian, Axel Heidenreich, Axel Haferkamp, Friedemann Zengerling, Pia Paffenholz: Multicenter analysis of serum tumor markers, treatment patterns, and relapse in patients with testicular cancer in clinical stage IS. Journal of Clinical Oncology, 2020 May; 38 (15_suppl), 5052-5052

[5] Stefan Hauser, Annette Kaminski, Isabella Syring, Stefan Holdenrieder, Klaus-Peter Dieckmann, Stefan C Muller, Jorg Ellinger: Evaluation of serum biomarkers (FGF-2, HGF, MIF and PTN) in patients with testicular germ cell cancer. in vivo; 2019 November; 33 (6), 1935-1940

[6] Maria Jung, Jörg Ellinger, Heidrun Gevensleben, Isabella Syring, Christine Lueders, Luka de Vos, Svenja Puetzer, Friedrich Bootz, Jennifer Landsberg, Glen Kristiansen, Dimo Dietrich: Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk
Stratification in Renal Cell Carcinoma Patients. A Prospective Observational Cohort Study. Clinical chemistry, 2019 April; 65 (4), 559-568

[7] Michael Gierth, Florian Zeman, Stefan Denzinger, Malte W Vetterlein, Margit Fisch, Patrick J Bastian, Isabella Syring, Jörg Ellinger, Stephan C Müller, Edwin Herrmann, Christian Gilfrich, Matthias May, Armin Pycha, Florian M Wagenlehner, Stefan Vallo, Georg Bartsch, Axel Haferkamp, Marc-Oliver Grimm, Jan Roigas, Chris Protzel, Oliver W Hakenberg, Hans-Martin Fritsche, Maximilian Burger, Atiqullah Aziz, Roman Mayr: Influence of body mass index on clinical outcome parameters, complication rate and survival after radical cystectomy: evidence from a prospective European multicentre study. Urologia Internationalis, 2018 May; 101 (1), 16-24

[8] Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J: The knockdown of the Mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells. Ann Diag Path. 2018 June; 34: 18-26

[9] Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J, Syring I: The tumor promotor role of the Mediator subunit MED15 in renal cell carcinoma. Cancer Biomark. 2018 Jan 19

[10] Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J: The knockdown of the Mediator complex subunit MED15 in urothelial bladder cancer cell lines and its effects on cell malignancy. Oncol lett. Accepted and in production

[11] Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer. Anticancer Res. 2017 Dec;37(12):6685-6695.

[12] Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.: Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clin Cancer Res. 2017 Apr 1;23(7):1829-1840.

[13] Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J, Perner S: Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Front Med (Lausanne). 2017 Mar 17; 4:30.

[14] Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.: MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget. 2017 Jan 31;8(5):7964-7976.

[15] Syring I, Klümper N, Offermann A, Braun M, Deng M, Boehm D, Queisser A, von Mässenhausen A, Brägelmann J, Vogel W, Schmidt D, Majores M, Schindler A, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.: Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget. 2016 Mar 30. Oncotarget Vol. 7, No. 17, pp 23043-55

[16] Schrödter S, Braun M, Syring I, Klümper N, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J.: Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. Mol Cancer. 2016 Feb 2;15(1):10. PMID: 26831905

[17] Syring I, Klümper N, Offermann A; Shaikhibrahim Z; Vogel W; Müller SC; Ellinger J; Strauß A; Radzun HJ; Ströbel P; Brägelmann J; Perner S; Bremmer F: Differential expression of Mediator Complex subunit MED15 in testicular germ cell tumours. Diagnostic Pathology. Diagn Pathol. 2015 Sep 17;10:165

[18] Müller FE, Braun M, Syring I, Klümper N, Schmidt D, Perner S, Hauser S, Müller SC, Ellinger J.: NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. Am J Cancer Res. 2015 Aug 15;5(9):2816-22. PMID: 26609487

[19] Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S, Müller SC.: The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res. 2015 Aug 15;5(9):2799-807.

[20] Blondeau JJ, Deng M, Syring I, Schrödter S, Schmidt D, Perner S, Müller SC, Ellinger J.: Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. Clin Epigenetics. 2015 Feb 8;7(1):10.

[21] von der Emde L, Goltz D, Latz S, Müller SC, Kristiansen G, Ellinger J, Syring I : Prostaglandin Receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. Am J Cancer Res. 2014 Nov 19;4(6):952-62.

[22] Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J: Circulating serum microRNA (miR-367-3p, miR-371a-3p, miR-372-3p, miR-373-3p) as biomarkers for patients with malignant testicular germ cell cancers. J Urol. 2014 Jul 18.

[23] Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocr Relat Cancer. 2014 Aug;21(4):663-75. Epub 2014 Jun 17.

[24] Kleinen L, Syring I, Laube N.: Reduction of biofilm formation on a-C:H coated implants: investigation of biofilm-surfaceinteractions by variation of thin film properties. Plasma Processes and Polymers 2009; 6: 41-45.

[25] Laube N, Kleinen L, Böde U, Fisang C, Meißner A, Bradenahl J, Syring I, Busch H, Pinkowski W, Müller SC: Plasmadeponierte funktionalisierte Kohlenstoffschichten zur Minderung von Inkrustationen auf urologischen Implantaten. Sonderband „Urologische Forschung Deutschland, Österreich und der Schweiz“. Der Urologe 2007; 46: 1249-1251.

Lectures

a) List of own scientific lectures and poster presentations with abstract

Lectures:

‍
[1] Syring I, Weiten R, Schmidt D, Müller T, Steiner S, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.: Der Knockdown der Mediatorkomplex Untereinheit MED30 unterdrückt die Proliferation und Migration von Nierenzellkarzinomzellen. V07.5, 69. Kongress der Deutschen Gesellschaft für Urologie, Dresden, 20. – 23. September 2017

[2] Syring I, Weiten R, Klümper N, Schmidt D, Müller T, Steiner S, Kristiansen G, Shaikhibrahim Z, Müller SC, Ellinger J, Perner S: The role of MED30 in the progression of urothelial carcinoma. V5.3, 8. Symposium des Arbeitskreises urologischer Forschung (AUF), Bonn, 24. – 26.11.2016 Platform presentation

[3] Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M, Böhm D, Queisser A, von Mäßenhausen A, Brägelmann J, Ellinger J, Müller SC, Perner S: The Mediator complex subunit MED8 is implicated in the progression of renal cell carcinoma. 62. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie, 14. - 15.04.2016, Münster. Platform presentation

[4] Syring, I, Klümper N, Offermann A, Braun M, Deng M, Böhm D, Queisser A, von Mäßenhausen A, Nowak M, Vogel W, Ellinger J, Müller SC, Shaikhibrahim Z, Perner S: The downregulation of MED12 is implicated in the progression and metastasis of urinary bladder cancer. 39. Preisverleihung und Jahrestreffen der C.E. ALKEN-Preisträger, Rottach-Egern 26. bis 28. November 2015

[5] Syring, I.; Klümper, N.; Böhm, D.; Offermann, A.; Braun, M.; Deng, M.; Queisser, A.; von Mäßenhausen, A.; Vogel, W.; Seitz, A.K.; Dyrskjøt, L.; Shaikhibrahim, Z.; Ellinger, J.; Müller, S.C.; Perner, S., Bonn, Aarhus, Dänemark: The downregulation of MED12 is implicated in the progression and metastasis of urinary bladder cancer. 67. Kongress der Deutschen Gesellschaft für Urologie, Hamburg, 23. – 26. September 2015

[6] Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M, Böhm D, Queisser A, von Mäßenhausen A, Ellinger J, Müller SC, Perner S: Die Bedeutung der Mediator-Komplex Untereinheit MED12 während der Progression des muskelinvasiven Blasenkarzinoms
61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie, Köln, 2015. Platform presentation; Verleihung des Paul-Mellin-Gedächtnispreises an Dr. med. Isabella Syring

[7] Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Kristiansen G, Wernert N Bubendorf L, Biskup S, Kirfel J, Perner S: Die Mediatorkomplex-Untereinheit MED15 als potenzieller Angriffspunkt neuer Therapeutika bei der Behandlung des kastrationsresistenten Prostatakarzinoms und als prognostischer Marker beim primären Prostatakarzinom. Symposium des Arbeitskreises urologischer Forschung (AUF) Symposium, Homburg, 13. – 15. November 2014

[8] Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Kristiansen G, Wernert N Bubendorf L, Biskup S, Kirfel J, Perner S: Die Mediatorkomplex-Untereinheit MED15 als potenzieller Angriffspunkt neuer Therapeutika bei der Behandlung des kastrationsresistenten Prostatakarzinoms und als prognostischer Marker beim primären Prostatakarzinom. 66. Kongress der Deutschen Gesellschaft für Urologie, Düsseldorf, 01 – 04. Oktober 2014

[9] Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Kristiansen G, Wernert N Bubendorf L, Biskup S, Kirfel J, Perner S: MED12 overexpression is a frequent event in castration-resitant prostate cancer. 66. Kongress der Deutschen Gesellschaft für Urologie, Düsseldorf, 01 – 04. Oktober 2014

[10] Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Kirfel J, Perner S: MED12 Überexpression im kastrationsresistenten Prostatakarzinom. 60. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie, 03.-04. April 2014, Düsseldorf.

[11] Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J (2013): Zirkulierende microRNAs (miR-320a, miR-302b, miR-302c, miR-371, miR-372, miR373) als Biomarker im Serum von Hodentumor-Patienten. 65. Kongress der Deutschen Gesellschaft für Urologie, Dresden, 25 – 28. September 2013

[12] Laube N, Kleinen L, Syring I (2008): Heterocoagulation processes on hydrophobic surfaces – key processes of crystalline bacterial biofilm formation on ureteral stents? 18. Symposium Experimentelle Urologie, Marburg, 10. – 12. April 2008.

Posterpräsentationen:

‍
[1] Syring I, Weiten R, Klümper N, Schmidt D, Müller T, Steiner S, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S: Knockdown of the mediator complex subunit MED30 suppresses proliferation and migration of renal cell carcinoma cells. 63rd Congress of the North Rhine-Westphalian Society of Urology, Essen, June 2017 Poster presentation. Award of the 1st poster prize to Dr. med. Isabella Syring

[2] Syring I., Klümper N., Shaikhibrahim Z., Offermann A., Braun M., Deng M., Böhm D., Queisser A., Von Mässenhausen A., Ellinger J., Müller S., Perner S: The Mediator complex subunit MED8 is implicated in the progression of papillary renal cell carcinoma. Congress of the European Association of Urology (EAU), Munich, March 2016. Moderated poster presentation; European Urology Supplements 15 (3), e120

[3] Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M, Böhm D, Queisser A, von Mäßenhausen A, Ellinger J, Müller SC, Perner S: The Mediator complex subunit MED12 is implicated in the progression of urothelial cell carcinoma of the bladder. American Urological Association Annual Meeting (AUA), New Orleans, May 2015. moderated poster presentation. The Journal of Urology, Volume 193, Issue 4, e860

[4] Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M, Böhm D, Queisser A, von Mäßenhausen A, Nowak M, Ellinger J, Müller S, Perner S: The Mediator complex subunit MED12 is implicated in the progression of urothelial cell carcinoma of the urinary bladder
Congress of the European Association of Urology, Madrid, March 2015. Moderated poster presentation. European Urology Supplements 14 (2), e756

[5] Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Nowak M, Halbach R, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Biskup S, Kirfel J, Perner S: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Congress of the European Association of Urology, Madrid, March 2015. Moderated poster presentation. European Urology Supplements 14 (2), e282

[6] Syring I, Bartels J, Holdenrieder S, Müller SC, Ellinger J (2013) Circulating microRNAs (miR-302a, miR-302b, miR-302c, miR-371, miR-372, miR373) as biomarkers in the serum of testicular tumor patients. 59th Congress of the North Rhine-Westphalian Society of Urology, April 11-12, 2013, Düsseldorf. Award of the 1st poster prize to Dr. med. Isabella Syring

[7] Laube N, Kleinen L, Syring I (2008) Are heterocoagulation processes on hydrophobic surfaces a key factor in the formation of incrustations on urological implants? 60th Congress of the German Society of Urology, Stuttgart, September 24 - 27, 2008. Der Urologe, 47 Suppl. 1, 2008, P1.4, S8

[8] Laube N, Kleinen L, Syring I, Bradenahl J (2007) The influence of albumin on the formation of crystal deposits on differently coated ureteral stents - amorphous carbon vs. polyurethane. 59th Congress of the German Society of Urology, September 26 - 29, 2007, Berlin
Urologist [A], Suppl. 1, 2007, PKLIN 8.1, S66. Best poster of the session.

[9] Laube N, Syring I, Bradenahl J, Kleinen L, Müller SC (2007) Crystal formation on differently coated ureteral stents as a function of urinary albumin concentration. 53rd Congress of the North Rhine-Westphalian Society of Urology, April 19 - 21, 2007, Cologne.

‍

Make an appointment
We are happy to accept your appointment request by phone or email:

Team

Priv.-Doz. Dr. Isabella Syring-Schmandke

Priv.-Doz. Dr. Isabella Syring-Schmandke

‍

Scientific contributions and publications